Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced it raised $35 million in Series A+ funding. This funding round was led by LongRiver Investments, with participation from investors including Zhaode Investment, BioTrack Capital, Zhongqi Capital and Lilly Asia Ventures. LongRiver Investments will join the board of Rona in connection with the funding.
Rona is advancing a pipeline of first-in-class siRNA programs generated from next generation siRNA platform. And the company’s first program RN0191, a best-in-class PCSK9 siRNA program, has completed Australia and China Ph1 clinical studies and ready for Ph2 clinical development for hypercholesterolemia.
RN0361 is the company’s second program entering clinic in the second quarter of this year for hypertriglyceridemia. The company is also advancing innovative pipeline at IND enabling stage for kidney disease, obesity and cardiometabolic diseases.
KEY QUOTES:
“Rona Therapeutics has successfully brought two best-in-class siRNA metabolic programs into global development and demonstrated differentiated clinical data and platform value. We are impressed by the progress Rona has made in developing innovative siRNA pipeline and expanding into extrahepatic delivery in CNS and beyond. We look forward to partnering with Rona team to unlock potential of RNA medicine as transformative therapies to patients globally.”
“We are thrilled to welcome LongRiver Investments and our other new investors as we progress more best-in-class and first-in-class siRNA programs into global development and catalyzing potential business development opportunities. Rona Therapeutics remains committed to pushing boundaries of RNA medicine in metabolic, obesity, renal and neuro degenerative diseases with Rona’s proprietary RNA platform.”
– Stella Shi, CEO and Founder of Rona Therapeutics
